FAM111A: A Promising Drug Target and Biomarker for Serine Protease-Driven Diseases

Target Name: FAM111A

NCBI ID: G63901

FAM111A: A Promising Drug Target and Biomarker for Serine Protease-Driven Diseases

Introduction

Serine proteases are a ubiquitous family of enzymes that play critical roles in various cellular processes. Among the many serine proteases, the focus of this article is on FAM111A, a protein that has garnered significant interest due to its unique structure and biology. FAM111A is a member of the MATK (Mutated ataxia-telangectasin-proteinase) family, which is characterized by the presence of a distinct N-terminal hypervariable region (HVR) and a unique catalytic mechanism that involves a unique substrate-protein interaction.

FAM111A's unique features make it an attractive drug target and biomarker for a variety of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. In this article, we will explore the biology and clinical potential of FAM111A, as well as its potential as a drug target and biomarker.

The Biology of FAM111A

FAM111A is a 21-kDa protein that is expressed in various tissues, including brain, heart, liver, and pancreas. Its unique structure consists of a 111-amino acid protein that possesses a N-terminal HVR and a C-terminal catalytic domain. The HVR is a 20-amino acid region that is highly conserved across various species and is known for its role in substrate recognition and protein-protein interactions. The C-terminal domain is a 96-amino acid region that contains the serine protease active site and is responsible for the protein's unique catalytic mechanism.

FAM111A's unique catalytic mechanism allows it to hydrolyze a wide range of serine proteases with high specificity and accuracy. This is achieved through a unique N-terminal interaction, where the protein's HVR interacts with the active site of the target protease, leading to a more specific and efficient cleavage of the target protein. In addition to its unique catalytic mechanism, FAM111A also possesses a number of other biological properties that make it an attractive drug target, including:

1. Diverse substrates: FAM111A can hydrolyze a wide range of serine proteases, including caseinases, elastases, and thrombin. This makes it an attractive drug target for various diseases caused by these enzymes, such as cancer, neurodegenerative disorders, and autoimmune diseases.
2. Cellular localization: FAM111A is predominantly localized to the endoplasmic reticulum (ER) and perinositol granules in the cytosol of various cell types. This is in contrast to other serine proteases, which are predominantly located in the cytosol and other organelles. This subcellular localization makes FAM111A a potential drug target that can be targeted directly without the need for complex biochemical assays.
3. Posttranslational modification: FAM111A can be modified posttranslationally through phosphorylation, which may influence its catalytic activity and stability. This provides a potential mechanism for modulating FAM111A's activity and making it more potent as a drug target.

Clinical potential of FAM111A as a drug target

FAM111A's unique biology and structure make it an attractive drug target for various diseases. The potential therapeutic applications of FAM111A are vast, and several studies have investigated its potential as a potential drug target.

1. Neurodegenerative diseases: FAM111A has been shown to play a role in the pathogenesis of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The HVR of FAM111A has been shown to interact with the

Protein Name: FAM111 Trypsin Like Peptidase A

Functions: Single-stranded DNA-binding serine protease that mediates the proteolytic cleavage of covalent DNA-protein cross-links (DPCs) during DNA synthesis, thereby playing a key role in maintaining genomic integrity (PubMed:32165630). DPCs are highly toxic DNA lesions that interfere with essential chromatin transactions, such as replication and transcription, and which are induced by reactive agents, such as UV light or formaldehyde (PubMed:32165630). Protects replication fork from stalling by removing DPCs, such as covalently trapped topoisomerase 1 (TOP1) adducts on DNA lesion, or poly(ADP-ribose) polymerase 1 (PARP1)-DNA complexes trapped by PARP inhibitors (PubMed:32165630). Required for PCNA loading on replication sites (PubMed:24561620). Promotes S-phase entry and DNA synthesis (PubMed:24561620)

More Common Targets